OBJECTIVE: To evaluate blood gases and ventilatory parameters before and after two doses of surfactant in premature infants with respiratory decompensation after recovery from primary respiratory distress syndrome (RDS). STUDY DESIGN: This prospective pilot study enrolled infant's > or =500 g birth weight, from 7 days to 3 months of age, with a secondary respiratory decompensation lasting at least 4 h prior to study entry. Infants received two doses of surfactant, 12 h apart. RESULT: A total of 20 neonates qualified for secondary surfactant administration. PCO2 (P<0.001); pH (P<0.001); mean airway pressure (P<0.05); FiO2 (P<0.05); modified ventilatory indices (P<0.004) and respiratory severity scores (P<0.001) improved significantly at both 12 and 24 h after surfactant administration. CONCLUSION: Secondary surfactant administration may be effective in reducing short-term ventilatory requirements in neonates who have a respiratory decompensation after recovery from initial RDS. Randomized controlled trials are needed to confirm these preliminary findings.
OBJECTIVE: To evaluate blood gases and ventilatory parameters before and after two doses of surfactant in premature infants with respiratory decompensation after recovery from primary respiratory distress syndrome (RDS). STUDY DESIGN: This prospective pilot study enrolled infant's > or =500 g birth weight, from 7 days to 3 months of age, with a secondary respiratory decompensation lasting at least 4 h prior to study entry. Infants received two doses of surfactant, 12 h apart. RESULT: A total of 20 neonates qualified for secondary surfactant administration. PCO2 (P<0.001); pH (P<0.001); mean airway pressure (P<0.05); FiO2 (P<0.05); modified ventilatory indices (P<0.004) and respiratory severity scores (P<0.001) improved significantly at both 12 and 24 h after surfactant administration. CONCLUSION: Secondary surfactant administration may be effective in reducing short-term ventilatory requirements in neonates who have a respiratory decompensation after recovery from initial RDS. Randomized controlled trials are needed to confirm these preliminary findings.
Authors: Roberta L Keller; Jeffrey D Merrill; Dennis M Black; Robin H Steinhorn; Eric C Eichenwald; David J Durand; Rita M Ryan; William E Truog; Sherry E Courtney; Philip L Ballard; Roberta A Ballard Journal: Pediatr Res Date: 2012-10-04 Impact factor: 3.756
Authors: James L Wynn; Matthew S Kelly; Daniel K Benjamin; Reese H Clark; Rachel Greenberg; Daniel K Benjamin; P Brian Smith Journal: Am J Perinatol Date: 2016-12-06 Impact factor: 3.079